Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 11/20 | 0.82 |
| ▸ | MEN1 | O00255 | 11/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.82 |
| ▸ | NPC1 | O15118 | 11/20 | 0.82 |
| ▸ | RAB9A | P51151 | 11/20 | 0.82 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.78 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.78 |
| ▸ | RELA | Q04206 | 3/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.76 |
| ▸ | HTT | P42858 | 5/20 | 0.76 |
| ▸ | GAA | P10253 | 2/20 | 0.76 |
| ▸ | HPGD | P15428 | 5/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.72 |
| ▸ | LMNA | P02545 | 4/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.72 |
| ▸ | PRNP | P04156 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | CASP3 | P42574 | 1/20 | 0.72 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8280120 | 0.88 | NPC1 (0.70) | MAPTSMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL2114859 | 0.87 | NPC1 (0.68) | MAPTSMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL2759505 | 0.87 | MAPT (0.86) | MAPTSMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL14880886 | 0.85 | MAPT (0.84) | MAPTSMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL2759560 | 0.84 | RAB9A (0.65) | MAPTSMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL22600051 | 0.84 | ATAD2 (0.65) | MAPTSMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL2733120 | 0.84 | NPC1 (0.65) | MAPTSMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL10531711 | 0.83 | NPC1 (0.63) | MAPTSMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL211763 | 0.83 | NPC1 (0.64) | MAPTSMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL10531725 | 0.83 | NPC1 (0.63) | MAPTSMN1; SMN2MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1706398-B1 | Amino-benzazoles as P2Y1 receptor inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8053450-B2 | P2Y1 Purinoreceptor; thromboembolic disorders; compounds are 2-((hetero)arylamino) benzimidazoles, benzoxazoles or benzothiazoles such as [2-(2-tert-butyl-phenoxy)-pyridin-3-yl]-(6-methyl-1H-benzoimidazol-2-yl)-amine | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-08 | — | — | US | disclosed |
| US-7470712-B2 | Amino-benzazoles as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080275090-A1 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS WITH PYRIDINE RING AND HETEROCYCLIC COMPONENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-06 | — | — | US | disclosed |
| EP-1706398-A1 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2006-10-04 | — | — | EP | disclosed |
| US-20050203146-A1 | Amino-benzazoles as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-15 | — | — | US | disclosed |
| WO-2005070920-A1 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-04 | — | — | WO | disclosed |
| US-4369323-A | Process for the manufacture of 2,2'-imino-bis-benzothiazole compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-01-18 | — | — | US | disclosed |
| EP-0029940-A1 | Process for the preparation of 2,2'-imino-bis benzothiazole compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203146-A1 | Amino-benzazoles as P2Y1 receptor inhibitors | P2RY1, P2RY11, P2RY2 | MAPT 4134/4885SMN1; SMN2 3860/4885MEN1 2514/4885 |
| US-20080275090-A1 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS WITH PYRIDINE RING AND HETEROCYCLIC COMPONENTS | P2RY1, P2RY11, P2RY2 | MAPT 4033/4885SMN1; SMN2 3992/4885MEN1 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.